- Home
- Publications
- Publication Search
- Publication Details
Title
Trial Watch
Authors
Keywords
-
Journal
OncoImmunology
Volume 3, Issue 3, Pages e27878
Publisher
Informa UK Limited
Online
2014-04-25
DOI
10.4161/onci.27878
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Docetaxel, oxaliplatin and capecitabine (TEX regimen) in patients with metastatic gastric or gastro-esophageal cancer: Results of a multicenter phase I/II study
- (2013) Alexander Stein et al. ACTA ONCOLOGICA
- Phase II Clinical Trial of Oxaliplatin and Bevacizumab in Refractory Germ Cell Tumors
- (2013) Amit Jain et al. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
- Long-term follow-up of a phase III study comparing radiotherapy with or without weekly oxaliplatin for locoregionally advanced nasopharyngeal carcinoma
- (2013) X. Wu et al. ANNALS OF ONCOLOGY
- ROS-induced autophagy in cancer cells assists in evasion from determinants of immunogenic cell death
- (2013) Abhishek D. Garg et al. Autophagy
- Autophagy-dependent ATP release from dying cells via lysosomal exocytosis
- (2013) Yidan Wang et al. Autophagy
- Pro-apoptotic signaling induced by photo-oxidative ER stress is amplified by Noxa, not Bim
- (2013) Tom Verfaillie et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Cancer immunogenicity, danger signals, and DAMPs: What, when, and how?
- (2013) Abhishek D. Garg et al. BIOFACTORS
- Prospective, open, multi-centre phase I/II trial to assess safety and efficacy of neoadjuvant radiochemotherapy with docetaxel and oxaliplatin in patients with adenocarcinoma of the oesophagogastric junction
- (2013) Markus Moehler et al. BMC CANCER
- A phase 1b study of humanized KS-interleukin-2 (huKS-IL2) immunocytokine with cyclophosphamide in patients with EpCAM-positive advanced solid tumors
- (2013) Joseph P Connor et al. BMC CANCER
- A randomised multicentre phase II study with cisplatin/docetaxel vs oxaliplatin/docetaxel as first-line therapy in patients with advanced or metastatic non-small cell lung cancer
- (2013) A Atmaca et al. BRITISH JOURNAL OF CANCER
- A phase 1 trial of imatinib, bevacizumab and metronomic cyclophosphamide in advanced colorectal cancer
- (2013) R K Kelley et al. BRITISH JOURNAL OF CANCER
- A multi-institutional phase 2 study of neoadjuvant gemcitabine and oxaliplatin with radiation therapy in patients with pancreatic cancer
- (2013) Edward J. Kim et al. CANCER
- Sequential chemoimmunotherapy of fludarabine, mitoxantrone, and cyclophosphamide induction followed by alemtuzumab consolidation is effective in T-cell prolymphocytic leukemia
- (2013) Georg Hopfinger et al. CANCER
- Role of Macrophage Targeting in the Antitumor Activity of Trabectedin
- (2013) Giovanni Germano et al. CANCER CELL
- A phase I trial of oxaliplatin in combination with docetaxel in patients with advanced solid tumors
- (2013) Syma Iqbal et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- A phase II trial of androgen deprivation therapy (ADT) plus chemotherapy as initial treatment for local failures or advanced prostate cancer
- (2013) Robert Amato et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- A phase II study of gemcitabine and oxaliplatin in advanced transitional cell carcinoma of the bladder
- (2013) Zeynep Eroglu et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Phase I clinical and pharmacokinetic/pharmacogenetic study of a triplet regimen of S-1/irinotecan/oxaliplatin in patients with metastatic colorectal or gastric cancer
- (2013) Sook Ryun Park et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- A multicenter phase II study of docetaxel, oxaliplatin, and bevacizumab in first-line therapy for unresectable locally advanced or metastatic non-squamous cell histology non-small-cell lung cancer (NSCLC)
- (2013) Luis E. Raez et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- A phase II study of neoadjuvant docetaxel, oxaliplatin, and S-1 (DOS) chemotherapy followed by surgery and adjuvant S-1 chemotherapy in potentially resectable gastric or gastroesophageal junction adenocarcinoma
- (2013) Inkeun Park et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- A randomized phase II study of weekly docetaxel/cisplatin versus weekly docetaxel/oxaliplatin as first-line therapy for patients with advanced gastric cancer
- (2013) Young Saing Kim et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Effects of cyclophosphamide and IL-2 on regulatory CD4+ T cell frequency and function in melanoma patients vaccinated with HLA-class I peptides: impact on the antigen-specific T cell response
- (2013) Chiara Camisaschi et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- CCL2/CCR2-Dependent Recruitment of Functional Antigen-Presenting Cells into Tumors upon Chemotherapy
- (2013) Yuting Ma et al. CANCER RESEARCH
- Danger signalling during cancer cell death: origins, plasticity and regulation
- (2013) A D Garg et al. CELL DEATH AND DIFFERENTIATION
- Molecular mechanisms of ATP secretion during immunogenic cell death
- (2013) I Martins et al. CELL DEATH AND DIFFERENTIATION
- Phase I-II Clinical Trial of Oxaliplatin, Fludarabine, Cytarabine, and Rituximab Therapy in Aggressive Relapsed/Refractory Chronic Lymphocytic Leukemia or Richter Syndrome
- (2013) Apostolia M. Tsimberidou et al. Clinical Lymphoma Myeloma & Leukemia
- Inducers of immunogenic cancer cell death
- (2013) Aleksandra M. Dudek et al. CYTOKINE & GROWTH FACTOR REVIEWS
- Chemotherapy and immunomodulation: from immunogenic chemotherapies to novel therapeutic strategies
- (2013) Francois Ghiringhelli et al. Future Oncology
- Docetaxel, oxaliplatin, and capecitabine combination chemotherapy for metastatic gastric cancer
- (2013) Luigi Di Lauro et al. Gastric Cancer
- A Multicenter Phase II Trial of Gemcitabine Plus Oxaliplatin in Unresectable Gallbladder Cancer
- (2013) Sang Myung Woo et al. Gut and Liver
- Anticancer Chemotherapy-Induced Intratumoral Recruitment and Differentiation of Antigen-Presenting Cells
- (2013) Yuting Ma et al. IMMUNITY
- Mechanism of Action of Conventional and Targeted Anticancer Therapies: Reinstating Immunosurveillance
- (2013) Laurence Zitvogel et al. IMMUNITY
- A Phase 2 Study of Oxaliplatin Combined With Continuous Infusion Topotecan for Patients With Previously Treated Ovarian Cancer
- (2013) Stacey M. Stein et al. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
- Phase I study of sunitinib plus capecitabine/cisplatin or capecitabine/oxaliplatin in advanced gastric cancer
- (2013) K.-W. Lee et al. INVESTIGATIONAL NEW DRUGS
- A Phase I Study of the combination of oxaliplatin/docetaxel and vandetanib for the treatment of advanced gastroesophageal cancer
- (2013) Balazs Halmos et al. INVESTIGATIONAL NEW DRUGS
- Multicenter phase II study of oxaliplatin and sorafenib in advanced gastric adenocarcinoma after failure of cisplatin and fluoropyrimidine treatment. A gemcad study
- (2013) M. Martin-Richard et al. INVESTIGATIONAL NEW DRUGS
- A phase I trial of bortezomib in combination with epirubicin, carboplatin and capecitabine (ECarboX) in advanced oesophagogastric adenocarcinoma
- (2013) R. C. Turkington et al. INVESTIGATIONAL NEW DRUGS
- Neoadjuvant and adjuvant chemotherapy with high-dose ifosfamide, doxorubicin, cisplatin and high-dose methotrexate in non-metastatic osteosarcoma of the extremities: a phase II trial in Japan
- (2013) Ikuo Kudawara et al. JOURNAL OF CHEMOTHERAPY
- Randomized, Multicenter, Open-Label Study of Oxaliplatin Plus Fluorouracil/Leucovorin Versus Doxorubicin As Palliative Chemotherapy in Patients With Advanced Hepatocellular Carcinoma From Asia
- (2013) Shukui Qin et al. JOURNAL OF CLINICAL ONCOLOGY
- Gemcitabine-oxaliplatin (GEMOX) as salvage treatment in pretreated epithelial ovarian cancer patients
- (2013) Patrizia Vici et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial
- (2013) Tom Waddell et al. LANCET ONCOLOGY
- Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial
- (2013) Charles Butts et al. LANCET ONCOLOGY
- Pegylated liposomal doxorubicin as third-line chemotherapy in patients with metastatic transitional cell carcinoma of urothelial tract: results of a phase II study
- (2013) Antonio Rozzi et al. MEDICAL ONCOLOGY
- Metabolic targets for cancer therapy
- (2013) Lorenzo Galluzzi et al. NATURE REVIEWS DRUG DISCOVERY
- A Phase II Study of Capecitabine, Oxaliplatin, and Bevacizumab in the Treatment of Metastatic Esophagogastric Adenocarcinomas
- (2013) H. E. Uronis et al. ONCOLOGIST
- A phase I study of oxaliplatin and doxorubicin in pediatric patients with relapsed or refractory extracranial non-hematopoietic solid tumors
- (2013) Leo Mascarenhas et al. PEDIATRIC BLOOD & CANCER
- Commensal Bacteria Control Cancer Response to Therapy by Modulating the Tumor Microenvironment
- (2013) N. Iida et al. SCIENCE
- The Intestinal Microbiota Modulates the Anticancer Immune Effects of Cyclophosphamide
- (2013) S. Viaud et al. SCIENCE
- Immunomonitoring and prognostic relevance of neutrophils in clinical trials
- (2013) Frede Donskov SEMINARS IN CANCER BIOLOGY
- Immunosurveillance as a regulator of tissue homeostasis
- (2013) Laura Senovilla et al. TRENDS IN IMMUNOLOGY
- Phase I clinical trial combining imatinib mesylate and IL-2
- (2013) Nathalie Chaput et al. OncoImmunology
- Tumor necrosis factor is dispensable for the success of immunogenic anticancer chemotherapy
- (2013) Yuting Ma et al. OncoImmunology
- Trial Watch: Lenalidomide-based immunochemotherapy
- (2013) Michaela Semeraro et al. OncoImmunology
- Phase I clinical trial combining imatinib mesylate and IL-2 in refractory cancer patients
- (2013) Patricia Pautier et al. OncoImmunology
- Trial Watch
- (2013) Erika Vacchelli et al. OncoImmunology
- Continuous 4–1BB co-stimulatory signals for the optimal expansion of tumor-infiltrating lymphocytes for adoptive T-cell therapy
- (2013) Jessica Ann Chacon et al. OncoImmunology
- Following up tumor-specific regulatory T cells in cancer patients
- (2013) Laurence Zitvogel et al. OncoImmunology
- Inhibiting the inhibitors
- (2013) Domenico Mavilio et al. OncoImmunology
- Trabectedin
- (2013) Paola Allavena et al. OncoImmunology
- ATP-dependent recruitment, survival and differentiation of dendritic cell precursors in the tumor bed after anticancer chemotherapy
- (2013) Yuting Ma et al. OncoImmunology
- Trial Watch
- (2013) Erika Vacchelli et al. OncoImmunology
- Trial watch
- (2013) Laura Senovilla et al. OncoImmunology
- Immune effects of 5-fluorouracil
- (2013) François Ghiringhelli et al. OncoImmunology
- Trial watch
- (2013) Erika Vacchelli et al. OncoImmunology
- Trial watch
- (2013) Laurie Menger et al. OncoImmunology
- Efficacy and Safety of Docetaxel Combined With Oxaliplatin as a Neoadjuvant Chemotherapy Regimen for Chinese Triple-Negative Local Advanced Breast Cancer Patients
- (2012) Fei Fei et al. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
- A Two-cohort Phase I Study of Weekly Oxaliplatin and Gemcitabine, Then Oxaliplatin, Gemcitabine, and Erlotinib During Radiotherapy for Unresectable Pancreatic Carcinoma
- (2012) Laura Raftery et al. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
- Immunogenic Cell Death in Cancer Therapy
- (2012) Guido Kroemer et al. Annual Review of Immunology
- Methotrexate-paclitaxel-epirubicin-carboplatin as second-line chemotherapy in patients with metastatic transitional cell carcinoma of the bladder pretreated with cisplatin-gemcitabine: A phase II study
- (2012) Amal Halim et al. Asia-Pacific Journal of Clinical Oncology
- A phase 2 clinical trial of sequential neoadjuvant chemotherapy with ifosfamide, doxorubicin, and gemcitabine followed by cisplatin, gemcitabine, and ifosfamide in locally advanced urothelial cancer
- (2012) Arlene O. Siefker-Radtke et al. CANCER
- Capecitabine and oxaliplatin in combination as first- or second-line therapy for metastatic breast cancer: a Wisconsin Oncology Network trial
- (2012) U. O. Njiaju et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Sorafenib Has Potent Antitumor Activity against Multiple Myeloma In Vitro, Ex Vivo, and In Vivo in the 5T33MM Mouse Model
- (2012) P. Kharaziha et al. CANCER RESEARCH
- Phase I and Clinical Pharmacology Study of Bevacizumab, Sorafenib, and Low-Dose Cyclophosphamide in Children and Young Adults with Refractory/Recurrent Solid Tumors
- (2012) F. Navid et al. CLINICAL CANCER RESEARCH
- Optimizing Cancer Treatments to Induce an Acute Immune Response: Radiation Abscopal Effects, PAMPs, and DAMPs
- (2012) C. M. Ludgate CLINICAL CANCER RESEARCH
- Targeting the Tumor Microenvironment for Cancer Therapy
- (2012) N. E. Sounni et al. CLINICAL CHEMISTRY
- Enlightening the impact of immunogenic cell death in photodynamic cancer therapy
- (2012) Lorenzo Galluzzi et al. EMBO JOURNAL
- A novel pathway combining calreticulin exposure and ATP secretion in immunogenic cancer cell death
- (2012) Abhishek D Garg et al. EMBO JOURNAL
- AEZS-108: a targeted cytotoxic analog of LHRH for the treatment of cancers positive for LHRH receptors
- (2012) Joerg Engel et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Immunogenic cell death biomarkers HMGB1, RAGE, and DNAse indicate response to radioembolization therapy and prognosis in colorectal cancer patients
- (2012) Yvonne Nadine Fahmueller et al. INTERNATIONAL JOURNAL OF CANCER
- Phase I trial of docetaxel, oxaliplatin, and capecitabine (DOC) in untreated gastric cancer patients
- (2012) Sergio Frustaci et al. International Journal of Clinical Oncology
- A phase II study to evaluate the efficacy and toxicity of oxaliplatin in combination with gemcitabine in carcinoma of unknown primary
- (2012) Heather Carlson et al. International Journal of Clinical Oncology
- A phase I study of sorafenib, oxaliplatin and 2 days of high dose capecitabine in advanced pancreatic and biliary tract cancer: a Wisconsin oncology network study
- (2012) Noelle K. LoConte et al. INVESTIGATIONAL NEW DRUGS
- The secret ally: immunostimulation by anticancer drugs
- (2012) Lorenzo Galluzzi et al. NATURE REVIEWS DRUG DISCOVERY
- Mitochondria: master regulators of danger signalling
- (2012) Lorenzo Galluzzi et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Abscopal Effect in a Patient with Melanoma
- (2012) NEW ENGLAND JOURNAL OF MEDICINE
- Immunologic Correlates of the Abscopal Effect in a Patient with Melanoma
- (2012) Michael A. Postow et al. NEW ENGLAND JOURNAL OF MEDICINE
- An Immunosurveillance Mechanism Controls Cancer Cell Ploidy
- (2012) L. Senovilla et al. SCIENCE
- Cardiac Glycosides Exert Anticancer Effects by Inducing Immunogenic Cell Death
- (2012) L. Menger et al. Science Translational Medicine
- Circulating immunogenic cell death biomarkers HMGB1 and RAGE in breast cancer patients during neoadjuvant chemotherapy
- (2012) Oliver J. Stoetzer et al. TUMOR BIOLOGY
- Targeting of distinct signaling cascades and cancer-associated fibroblasts define the efficacy of Sorafenib against prostate cancer cells
- (2012) P Kharaziha et al. Cell Death & Disease
- Trial Watch
- (2012) Lorenzo Galluzzi et al. OncoImmunology
- Dendritic cell inhibition correlates with survival of colorectal cancer patients on bevacizumab treatment
- (2012) Adriana J. Michielsen et al. OncoImmunology
- Abscopal but desirable
- (2012) Guido Kroemer et al. OncoImmunology
- Trial Watch
- (2012) Erika Vacchelli et al. OncoImmunology
- Trial watch
- (2012) Erika Vacchelli et al. OncoImmunology
- Trial watch
- (2012) Laura Senovilla et al. OncoImmunology
- Trial watch
- (2012) Erika Vacchelli et al. OncoImmunology
- Trial watch
- (2012) Erika Vacchelli et al. OncoImmunology
- An anticancer therapy-elicited immunosurveillance system that eliminates tetraploid cells
- (2012) Laura Senovilla et al. OncoImmunology
- Molecular determinants of immunogenic cell death elicited by anticancer chemotherapy
- (2011) Oliver Kepp et al. CANCER AND METASTASIS REVIEWS
- Human Tumor Cells Killed by Anthracyclines Induce a Tumor-Specific Immune Response
- (2011) J. Fucikova et al. CANCER RESEARCH
- Tumor-Derived Autophagosome Vaccine: Mechanism of Cross-Presentation and Therapeutic Efficacy
- (2011) Y. Li et al. CLINICAL CANCER RESEARCH
- Global experience with ixabepilone in breast cancer
- (2011) Virginia G Kaklamani et al. Expert Review of Anticancer Therapy
- Induction of Immunogenic Apoptosis by Blockade of Epidermal Growth Factor Receptor Activation with a Specific Antibody
- (2011) Greta Garrido et al. JOURNAL OF IMMUNOLOGY
- Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
- (2011) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Molecular mechanisms of cisplatin resistance
- (2011) L Galluzzi et al. ONCOGENE
- Cancer Immunoediting: Integrating Immunity's Roles in Cancer Suppression and Promotion
- (2011) R. D. Schreiber et al. SCIENCE
- Cyclophosphamide Synergizes with Type I Interferons through Systemic Dendritic Cell Reactivation and Induction of Immunogenic Tumor Apoptosis
- (2010) G. Schiavoni et al. CANCER RESEARCH
- Patupilone in cancer treatment
- (2010) Branislav Bystricky et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Restoration of the immunogenicity of cisplatin-induced cancer cell death by endoplasmic reticulum stress
- (2010) I Martins et al. ONCOGENE
- Chemotherapy and radiotherapy: Cryptic anticancer vaccines
- (2010) Yuting Ma et al. SEMINARS IN IMMUNOLOGY
- Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study
- (2009) Jedd D Wolchok et al. LANCET ONCOLOGY
- Immunogenic death of colon cancer cells treated with oxaliplatin
- (2009) A Tesniere et al. ONCOGENE
- Improved Cellular Pharmacokinetics and Pharmacodynamics Underlie the Wide Anticancer Activity of Sagopilone
- (2008) J. Hoffmann et al. CANCER RESEARCH
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started